News Genmab A/S Nasdaq

Stocks

GMAB

US3723032062

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 13/08/2026 BST			5-day change	1st Jan Change
31.34 ^USD	-0.25%		+5.06%	+1.75%

06:08am	Nordic stocks in North America, Astra Zeneca fell 0.8%	FW
08-12	BNP Paribas Initiates Genmab at Outperform, With $40 Price Target	MT

All News

Mentions Relevance

08-12	BNP Paribas Initiates Genmab at Outperform, With $40 Price Target	MT
08-11	Capital Increase in Genmab as a Result of Employee Warrant Exercise	GL
08-07	Genmab: Q2 beat reinforces the investment story; diversification efforts remain on course
08-07	Genmab A/S, H1 2026 Earnings Call, Aug 06, 2026
08-07	UBS raises Genmab price target to 2,700 Danish kroner (2,600), reiterates buy	FW
08-07	Genmab soars after raising its guidance
08-07	Analysts upbeat on Genmab after strong Q2	FW
08-07	Goldman Sachs raises Genmab target price to 2,400 Danish kroner (2,350), reiterates buy - BN	FW
08-07	TD Cowen raises Genmab price target to 2,892 Danish kroner (2,851), reiterates buy	FW
08-07	Jyske Bank raises Genmab target price to 2 350 Danish kroner (2 300), reiterates buy - BN	FW
08-07	Nordea raises its target price for Genmab to 2,083 Danish kroner (2,015), reiterates buy	FW
08-06	Genmab A/S Revises Earnings Guidance for the Year 2026	CI
08-06	Genmab A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-06	Genmab Lifts FY26 Earnings Guidance	MT
08-06	Genmab boosts operating profit more than expected, raises guidance (update 2)	FW
08-06	Genmab A/S : Interim Report for the First Half of 2026	PU
08-06	Genmab boosted operating profit more than expected, raises forecasts (update)	FW
08-06	Genmab boosted operating profit more than expected	FW
08-06	Genmab Announces Financial Results for the First Half of 2026	GL
07-23	Stocks to Watch : Intel, Deckers, Edwards Lifesciences, Genmab	DJ
07-23	Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)	GL
07-23	Genmab A/S and AbbVie Provide Clarification on Phase 3 EPCORE DLBCL-1 Trial Evaluating Epcoritamab (DuoBody-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma	CI
07-22	TD Cowen Upgrades Genmab to Buy Rating, Boosts PT	MT
07-22	TD Cowen Upgrades Genmab to Buy From Hold, Raises Price Target to $43 From $32	MT
07-22	TD Cowen upgrades Genmab to buy (hold) - BN	FW